Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $942211.0.

  • bioAffinity Technologies' Cost of Revenue fell 3457.59% to $942211.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 1967.3%. This contributed to the annual value of $6.0 million for FY2024, which is 24370.33% up from last year.
  • As of Q3 2025, bioAffinity Technologies' Cost of Revenue stood at $942211.0, which was down 3457.59% from $1.0 million recorded in Q2 2025.
  • bioAffinity Technologies' Cost of Revenue's 5-year high stood at $1.7 million during Q4 2023, with a 5-year trough of $87.0 in Q1 2023.
  • Its 4-year average for Cost of Revenue is $789392.8, with a median of $979406.5 in 2025.
  • Per our database at Business Quant, bioAffinity Technologies' Cost of Revenue soared by 180845287.36% in 2024 and then crashed by 3457.59% in 2025.
  • bioAffinity Technologies' Cost of Revenue (Quarter) stood at $175.0 in 2022, then soared by 951248.0% to $1.7 million in 2023, then fell by 6.17% to $1.6 million in 2024, then tumbled by 39.69% to $942211.0 in 2025.
  • Its last three reported values are $942211.0 in Q3 2025, $1.0 million for Q2 2025, and $1.4 million during Q1 2025.